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The  term  cutaneous  basophil  hypersensitivity  (CBH) t  has  recently  been 
used to  describe  the  type  of  delayed  hypersensitivity  reaction  produced  tran- 
siently  early in  the  course  of  immunization  with  soluble  antigen  (1-3).  Im- 
munogenic  and  antigenic  requirements  distinguish  it  from  classic  delayed 
hypersensitivity  (classic  DH)  and  antibody-mediated  reactions  (2),  and  the 
histology  of  the  skin  reaction  is  uniquely  characterized  by heavy  infiltration 
with  basophils  (3).  CBtt  has  recently  been  reported  in  contact  dermatitis 2 
and  allograft  rejection  (4).  Studies  of  tolerogenesis  in  adult  guinea  pigs  by 
Asherson  and  Stone  (5)  revealed reduction  in  classic DH  by preimmunization 
injection  of  soluble  or  alum-precipitated  antigen  without  a  comparable  effect 
on  antibody  production;  this  phenomenon  was  called  "immune  deviation." 
Dvorak  et  al.  (6)  were  able  to  induce  specific immunologic  unresponsiveness 
to  human  serum  albumin  and  bovine  gamma  globulin  in  adult  guinea  pigs 
with  intravenous  injections  of  antigen  in  saline  within  3  wk  of  subsequent 
immunization  with  the  same  antigen  in  complete  Freund's  adjuvant  (CFA); 
classic DH  and  hemolytic  antibody  were  suppressed  more  completely and  for 
a  longer  time than was passive cutaneous  anaphylaxis  (PCA)  antibody. 
In  the  investigations  reported  here,  the  effects  of  intravenous  administra- 
tion  of  antigen  on  CBH  are  compared  with  tolerogenesis  toward  classic  DH 
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and  antibody  production.  Results  show  that  relatively  large  doses  of  in- 
travenous  ovalbumin  in  guinea  pigs  stimulate  immunogenesis  for  CBH  and 
PCA  antibody  while  at  the  same  time inducing  tolerance  for  classic DH  and 
hemolytic antibody. 
Materials and Methods 
Animals.--Random-bred  white guinea pigs  (weighing 3(D-400 g)  were  used in these ex- 
periments for active immunization and skin testing, and for measuring PCA antibody. 
Antigen.--Ovalbumin  (5x  crystallized,  Pentex  Biochemical,  Kankakee,  Ill.)  diluted  in 
saline was used throughout. PPD  (purified protein derivative of tuberculin) was purchased 
from Connaught Medical Research Laboratories, University of Toronto, Toronto, Canada, 
and diluted appropriately in saline. 
Toterogenesis ProtocoL--The  initial schedule for comparison of  tolerogenic requirements 
in CBH, classic DH, gamma1 and gamma2 antibody production is shown below: 
Day 0  Day 7  Day 14  Day 15  Day 28 
Intravenous ovalbumin (OA)  Skin test  Skin test  Immunize  Bleed for antibody 
(graded doses)  (100vg OA)  (100~g  OA)  (10~g  OAin CFA)  Skin  tests (10 vg OA 10 
~g PPD) 
Various doses of  ovalbumin  (OA)  were  injected intravenously into the hind foot  vein on 
day 0.  1 wk later,  100 #g of OA was injected intradermally in a  volume of 0.1  ml, which 
experience had shown immunizes the guinea pig for CBH  (see Results and Table IV).  At 
2 wk, the animal was again skin tested and the test read at 4 and 24 hr. Subsequent immuni- 
zation was carried out by injection of 10/zg of OA emulsified in CFA in a  total volume of 
0.1 ml divided equally among the four footpads. CFA was made with 8.5 parts light mineral 
oil and 5 parts Arlacel A  (Atlas Chemical Industries, Inc., Wilmington, Del.)  to which was 
added 5 mg/ml of  killed mycobacteria.  2 wk  after immunization  the  animals  were  bled 
for  antibody studies  and  skin  testing was  repeated using 10 #g of  OA to  judge tolerance 
for classic DH, and 10 #g  of  PPD  to  evaluate possible nonspecific  suppression.  Reactions 
were read  at 4  and  24  hr;  the  diameter  of  erythema, degree of  induration, and presence 
or absence of  necrosis were  recorded.  Later  studies  of sensitization  by  intravenous  anti- 
gen alone and  of  dose and  route  requirements  for  CBH sensitization are  detailed under 
Results. 
Antibody  S~udies.--Blood  was  collected  by  cardiac  puncture,  allowed  to  clot  at  room 
temperature, and the serum separated by centrifugation and stored frozen until examined. 
Passive cutaneous anaphylaxis was used to measure 7S gamma1 antibody (7). Serum dilutions 
in volume of 0.1 ml were injected intradermally in the back of duplicate guinea pigs at mul- 
tiple sites (up to 16). 4 hr later, a mixture of 20/0 Evan's blue dye and 1 mg of OA in a  total 
volume of 1 ml was injected intravenously; reactions were measured after  30  min.  Titers of 
7S gamma2 and macroglobulin (hemolytic) antibody were measured by hemolysis of antigen- 
coated  tanned sheep red cells by the method of Kabat and Mayer (8) as modified by Bloch 
et al.  (9).  A  concentration of 2 mg/ml of antigen was used  to coat the  tanned sheep cells. 
The highest dilution giving complete hemolysis was taken as the end point. 
Histology.--Histolo#cal  sections were kindly prepared in the laboratory of John C. Hoak, 
M.D.,  Hematology Section, Department of Internal Medicine,  University of Iowa. Tissues 
were  fixed  in  gluteraldehyde,  postfixed  in  osmium  tetroxide,  were  dehydrated  in  graded 
alcohol solutions and propylene, and were embedded in Epon Araldite. For light microscopy, 
1 #  sections were cut and stained for 1 hr in Giemsa diluted 1:10 in 2%  sodium  borate solu- 
tion. For electron microscopy, sections were cut on a  Reichert ultramicrotome  (C. Reichert, 632  CUTANEOUS  BASOPHIL  HYPERSENSITIVITY 
Wien, Austria) and  examined with a Philips EM 300 electron microscope (Philips Electronic 
Instruments,  Mount Vernon, N.Y.). 
RESULTS 
Tolerogenesis.--The  tolerogenesis  protocol  outlined  above  proved  suitable 
to demonstrate  differences in  tolerogenic  requirements  for  classic  DH,  PCA 
antibody,  and  hemolytic antibody.  Results  are given in Table  I.  After intra- 
TABLE I 
Results oJ Tolerogenesis Protocol 
~ose 
d 
i,v. 
Time  OA 
at 
day 
0 
wk  mg 
1  none 
1 
10 
100 
none 
1 
10 
100 
none 
1 
10 
100 
Delayed skin reaction to 
100 ~g OA 
0--  (6/6)* 
13--  (4/4) 
i5--  (4/4) 
4--  (2/6) 
18--  (6/6) 
o-  (0/4) 
early  rxn:~ (3/4) 
early rxn  (4/6) 
10 ~g OA 
18+++  (6/6) 
10+  (4/4) 
12+  (4/4) 
6--  (3/5) 
10 vg PPD 
19+++  (6/6) 
18+++  (4/4) 
19+++  (4/4) 
18+ + +  (5/5) 
Antibody response 
PCA 
(Average  Hemolytic 
titer)  (Average titerl 
600  (6/6)  2000 (6/6) 
520 (4/4)  112  (4/4) 
400  (4/4) 
150 (5/5)  45  (2/5) 
* Skin reactions are recorded as average diameter of erythema in millimeters followed by 
the average  degree of induration  graded from --  to +++.  Figures in parenthesis  denote 
No. of guinea pigs reacting per number tested. 
rxn, reaction. 
venous  injection  of  large  amounts  of  soluble  OA,  subsequent  immunization 
with OA in CFA resulted at 4 wk (2 wk postimmunization) in mild suppression 
of  PCA  titers,  markedly  diminished  hemolytic  antibody  titers,  and  specific 
suppression  of  classic  DH.  This  is  in  agreement  with  the  results  of  Dvorak 
et al. (6) using other antigens. 
Of great  interest,  however,  was  the  observation  that  the  delayed  skin  test 
7 days after  the  tolerogenic intravenous  OA injection  was frequently positive 
and  had  the  morphologic  characteristics  of  CBH.  At  14  days,  skin  testing 
resulted in an earlier reaction, probably antibody-mediated, reaching maximum 
intensity  at  4-6  hr  and  appearing  faded  at  24  hr  as  discussed  elsewhere  (3) HAL  B.  RICHERSON  633 
The control group showed good CBH reactivity at 2 wk,  1 wk after  the  initial 
skin  test  (see  Table  IV).  The  phenomenon  of immunization  for  CBH  by in- 
travenous  antigen  led  to further  studies  on the  effects of route and  dosage of 
OA on the immune response. 
Immune  Response  after  Intravenous  Antigen.--Studies  were  designed  to 
evaluate  the  immune  response  after  varying  doses  of intravenous  ovalbumin 
without subsequent immunization. Table II summarizes the results of one such 
experiment.  Groups  of  guinea  pigs  were  injected  with  log doses  of OA,  skin 
tested  at  7  days,  and bled weekly. The  control group was also skin  tested  at 
1 wk and bled weekly. CBH was present  7 days after intravenous injection  of 
OA, most consistently after a  dose of 1 mg. PCA antibody was not detectable 
in any of the groups tested on day 7 (lowest dilution tested was 1:10), but was 
regularly  present  14  days  after  intravenous  OA dosages  of  1,  10,  or  100  mg. 
TABLE II 
Immune Response after Intravenous Ovalbumln 
Delayed skin 
Dose given  rxn at 7 days to  2 wk  3 wk 
100 ~g OA 
PCAAb*  Hemolytic Ab 
Titer on pooled sera 
1:10  1:100  1:10  1:100  2 wk  3 wk 
100 mg OA i.v.  8--  (3/6):~  13  3  10.5  6  <1:2  <1:10 
10 mg OA i.v.  14--  (4/6)  6  0  14  12  <1:2  <1:10 
1 mg OA i.v.  17--  (6/6)  8  0  15  12  <1:2  <1:10 
Control  0--  (0/6)  0  0  11  0  <1:2  <1:10 
* PCA at stated dilutions was performed on pooled sera for each group and is recorded 
as average size of lesion (mm) in three passive recipients. Ab, antibody. 
See Table I for grading of skin reactions. 
No  hemolytic  antibody  was  detectable  at  any  time  after  administration  of 
intravenous  OA alone.  The control group was negative  throughout except for 
the presence  of PCA antibody 2  wk after  skin  testing  with  100 #g  of OA. A 
positive CBH reaction  can be regularly elicited  7  days after such skin  testing 
(see Tables I  and IV). 
A  second similar  experiment  was carried  out to eliminate  the effect of skin 
testing as a  possible booster for antibody formation,  and to examine for CBH 
earlier  than  the  7th  day  in  animals  receiving  100  mg  of  OA  intravenously. 
The results are summarized in Table III. After intravenous injection of 100 mg 
of  OA,  none  of  three  animals  developed  CBH  after  skin  testing  on  the  4th 
day,  whereas  six  of  seven  animals  showed  CBH  when  skin  tested  on  day 5. 
Skin  testing  made  little  difference  in  PCA  titers.  Animals  receiving  100  mg 
of OA intravenously  developed  slightly higher  PCA titers  14 days later  than 
did  animals  receiving  1 mg of OA intravenously. No hemolytic antibodv was 
detectable. 634  CUTANEOUS  BASOPHIL  HYPERSENSITIVITY 
F.ffect of Route and Antigen Dose on Sensitization for CBH.--Previous studies 
have concluded  that minute doses of antigen  are effective for the  production 
of  CBH  (10).  The  above findings  with  the  intravenous  route  and  skin  test 
immunization  raised  the  question  of whether  dosage requirements for subse- 
quent CBH varied with the route of administration of the antigen. Results of 
studies  addressed  to  this question  are summarized in Table IV.  Clear differ- 
ences  occur  among  the  three  routes  of immunization  in  respect  to  optimum 
dosage for  CBH  when  tested  7  days later.  When  OA  is  incorporated  in  in- 
complete Freund's  adjuvant  (IFA)  and  injected  into  footpads,  the  optimum 
dose is about 1 #g.  When  soluble antigen is injected  intravenously, however, 
a  1000-fold  higher  optimum  dose  of DBH is noted,  i.e.,  about  1 rag.  When 
animals  are  sensitized  by injecting  soluble  OA  as  a  skin  test,  the  optimum 
TABLE III 
Immune Response after Intravenous Ovalbumin (Continued) 
Dose of OA i.v. at  Delayed skin rxn to  100 gg OA  PCA titer at day 14  Hemolysin 
day 0  Day 4  Day 5  (average titer)  Titer day 14 
mg 
100  0--  (0/3)*  ND  32  (3/3):~  <1:2  (0/3) 
100  ND§  14--  (6/7)  20  (3/3)  <1:2  (0/3) 
100  ND  ND  36  (5/6)  <1:2  (0/6) 
1  ND  ND  13  (5/6)  <1:2  (0/6) 
* See Table I for grading of skin lesions. 
:~ PCA in these experiments is recorded as average titer of individual sera; figures in 
parenthesis denote animals reacting/number tested. 
§ ND =  not done. 
dosage is clearly less than by the intravenous route and more than that with 
emulsion into footpads. 
Histology  of Delayed  Skin  Lesions  Produced by Intravenous  and  Skin  Test 
Immunization.--An important consideration is whether the delayed skin reac- 
tion produced by intravenous or intradermal  injection  of soluble antigen  has 
the  histological  characteristics  of  CBH  produced  by  antigen  emulsified  in 
IFA and injected into footpads (1, 3). Grossly, the skin reactions are identical 
regardless  of  immunization  route;  at  24  hr  there  is  an  area  of  well-circum- 
scribed  erythema,  frequently  rather  faint  in  intensity,  unaccompanied  by 
induration,  and appearing faded in 48 hr.  Histological studies  of the delayed 
skin  reactions  after  immunization  with  soluble  antigen  intravenously  or 
intradermally  revealed  a  picture  identical  to  that  previously  described  of 
CBH (1, 3). Light microscopy revealed substantial accumulations of basophils 
accompanied by other  mononuclear  cells;  electron microscopy confirmed  the 
presence of groups of basophils (Figs.  1 and 2). Thus, the histological picture 
substantiates the identity of these reactions as CBH. HAL  B.  RICHERSON  635 
DISCUSSION 
The results described here indicate  that intravenous injection of relatively 
large  doses  of  ovalbumin  in  guinea  pigs,  sufficient  to  produce  subsequent 
tolerance with respect to classic delayed hypersensitivity and hemolytic anti- 
body,  actually  stimulates  the  development of  CBH  and  PCA  antibody.  In 
addition,  a  wide  variation  in  dosage  optimum  for  CBH  has  been  demon- 
strated to depend on route of immunization. 
Immune deviation and partial or split tolerance have been reported in adult 
guinea  pigs  given  soluble  or  alum-precipitated  antigen  before immunization 
with  the  same  antigen  emulsified in  CFA  (5,  6).  The question addressed in 
the present studies was whether tolerance for CBH could be produced relatively 
TABLE IV 
Effect of Route on Dosage Requirements for Optimum CBH 
Dose of OA for 
immunization 
Delayed skin reactivity at 7 days to 100 ttg OA after immunization  by route 
shown 
Footpads in IFA  i.d. skin test  Intravenous 
mg 
0.00001  0--  (0/6)*  0--  (0/4) 
0.0001  14--  (14/16)  5--  (1/4)  0--  (0/4) 
0.001  18--  (16/16)  11--  (3/4)  7--  (2/4) 
0.01  8--  (6/10)  12--  (6/8)  7--  (2/4) 
0.1  4--  (1/6)  14--  (8/10)  4--  (1/4) 
1.0  3--  (1/6)  13--  (4/4)  15--  (10/10) 
10.0  0--  (0/6)  0--  (0/4)  13--  (10/14) 
100.0  5--  (5/16) 
* See Table I for grading of skin reactions. 
easily, in which case it would in this respect resemble classic DH and gamma2 
(hemolytic) antibody, or whether tolerogenesis for CBH is difficult, in which 
respect it would then resemble gamma1 (PCA) antibody production. The tolero- 
genesis protocol confirmed earlier reports of partial tolerance, with classic DH 
and hemolytic antibody production being suppressed  by intravenous antigen 
before immunization  with  antigen  emulsified  in  CFA,  while  PCA  antibody 
production  was  less  affected. An  unexpected  finding  with  the  tolerogenesis 
protocol was  that  the intravenous  tolerogenic dose of antigen  sensitized  the 
animal  for  CBH.  After  intravenous  ovalbumin,  CBH  was  elicited  at  5-7 
days,  at  a  time when  no detectable antibody was  present in  the  serum.  By 
12-14  days,  PCA  but  not  hemolytic antibody was  demonstrable.  Thus,  in- 
travenous OA in doses sufficient to be tolerogenic for classic DH and hemolytic 
antibody actually produced both CBH and subsequent PCA antibody. 
Experiments  of  others  concerning  antigenic  requirements  for  Jones-Mote 
hypersensitivity concluded that very small amounts of antigen were necessary 636  CUTANEOUS  BASOPHIL  HYPERSENSITIVITY 
FIG.  1.  Electron  photomicrograph of delayed  skin reaction at  24 hr after  skin test with 
100 #g of ovalbumin (OA) in a  guinea pig sensitized 5  days earlier with 100 mg of OA intra- 
venously. Note cluster of basophils, a common scene throughout the sections. X  5600. Fro. 2. Electron photomicrograph of delayed skin lesion taken 24 hr after skin test with 
109 Izg of ovalbumin (OA) in guinea pig sensitized 7 days earlier with 10/zg of OA intrader- 
mally on flank.  Note accumulation of basophils, and  there is one eosinophil  (with ovoid 
granules containing central bar at higher magnification.) X  5600. 
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when injected in the soluble form (10). Our own findings confirm that low doses 
(i.e.  1 ~g)  are  optimal for CBH when ovalbumin is incorporated in IFA;  on 
the other hand, a  1000-fold larger dose is optimal for CBH sensitization when 
injected intravenously; and soluble OA injected intradermally as a  skin  test 
has intermediate dosage requirements. These differences may reflect a  subtle 
balance between tolerogenesis and immunogenesis, or may perhaps be due  to 
an antigen localization requirement for CBH stimulation. 
Very recently, Bast et al. (11, 12) have studied in vitro responses of lymphoid 
cells taken from animals made tolerant to human serum albumin  (HSA); the 
"tolerizing"  injection  of  HSA  was  given  intravenously  immediately  before 
immunization with HSA in CFA or IFA, and this routine resulted in a dimin- 
ished CBH response 1 wk but not 2 wk later. The effect of intravenous toleriz- 
ing antigen alone was not studied. The results of thymidine incorporation indi- 
cated  an  evolution of cellular immunity with  selection of lymphoid cells re- 
sponding  to  decreasing  concentrations  of  antigen  as  time  passed.  Cells  re- 
sponsive  at  low  antigen  concentration  evolved  later,  were  easily  rendered 
tolerant  by  intravenous  antigen,  and  were  correlated  with  classic  delayed 
hypersensitivity skin reactions. Cells responsive at high antigen concentration 
evolved earlier, were resistant to tolerogenic antigen, and correlated in vivo with 
CBH (11). The appearance of lymphocytes reacting to low concentrations of 
HSA was associated with a progressive increase in the degree of induration of 
delayed skin reactions, i.e., classic delayed hypersensitivity rather than CBH. 
Our own experiments could thus be interpreted as demonstrating a popula- 
tion of antigen-responsive cells which clone with high-dose antigen (even when 
administered  intravenously),  are  resistant  to  tolerogenesis,  and  participate 
in the CBH delayed skin reaction. The three routes of immunization employed 
may have different localizing propensities for delivery of antigen  to antigen- 
responsive cells, and thus vary in dosage requirements. 
Borel and David (13)  have reported that peritoneal exudate cells from par- 
tially tolerant guinea pigs fail to elaborate migration-inhibitory factor (MIF) 
when incubated with  the  tolerance-inducing antigen.  Bast  and  Dvorak  (14) 
also found MIF elaboration limited to classic DH, whereas blast transforma- 
tion occurred in lymphocyte cultures from animals sensitized either for CBH 
or  classic  DH,  with  differing time  and  dosage  relationships  (12).  Our  data 
support the correlation of indurated delayed skin reactions (i.e. classic delayed 
hypersensitivity)  with  the  presence  of  lymphocytes  capable  of  stimulation 
with low antigen concentrations and easily rendered tolerant; and, conversely, 
the correlation of CBH reactions with the appearance of lymphocytes stimu- 
lated by high-dose antigen  and  resistant  to tolerogenesis. In addition  to the 
evidence cited  above  on  MIF  production,  studies  with  carrageenan  suggest 
that a basic difference between classic DH and CBH is the role of the macro- 
phage,  which  participates  only  in  the  indurated  lesion  of  classic  DH  (2). HAL  ]3.  RICHERSON  639 
Presumably,  then,  a  high-affinity  lymphocyte  easily  rendered  tolerant  is 
responsible for classic DH and elaboration of MIF. 
The  significance for  clinical medicine of the  specific  cellular and antibody 
responses  to  high-dose intravenous  tolerizing  antigen  is  uncertain.  The  im- 
portance of lymphoid cells responding to high-dose antigen in allograft rejec- 
tion has not been determined, although Dvorak (4)  has found that skin allo- 
graft rejection in the guinea pig is associated with many of the morphologic 
features of  CBH.  The  production  of complete  tolerance by the  intravenous 
administration  of  soluble  transplantation  antigens  may  therefore  not  be  a 
practical possibility. The unfolding heterogeneity of the  cellular immune re- 
sponse increasingly complicates control of this type of hypersensitivity. 
The immunogenic-tolerogenic stimilarities between CBH and PCA (gamma1) 
antibody suggests  an  intrinsic  relationship between  these  two  types  of im- 
mune response.  Of interest is  that in  the  human,  as  originally described by 
Jones and Mote (15),  delayed hypersensitivity precedes  wheal-and-flare anti- 
body responses and reappears  as the latter wanes; similar observations  have 
been made in the guinea pig by Sell and Weigle (16). Of relevance also may be 
the report that delayed skin reactions may be "unmasked" if the  wheal-and- 
flare skin reaction is inhibited by antihistamines in grass  pollen-sensitive pa- 
tients (17).  Further work is required in the guinea pig to completely charac- 
terize the relationship between CBH and PCA antibody, particularly in view 
of the recent reports  of a  guinea pig IgE immunoglobulin class  (18,  19).  In- 
triguing, however, is  the  apparent  importance of the basophil in both  CBH 
and type I  (anaphylactic) hypersensitivity reactions (20).  It seems more than 
coincidence that CBH calls  the basophil to the site of action and PCA anti 
body utilizes the same cell to carry out its work. 
SUMMARY 
Cutaneous  basophil hypersensitivity  (CBH)  was studied for tolerogenic 
requirements. Graded doses  of intravenous  ovalbumin (OA) were given to 
guinea pigs  which were subsequently immunized  appropriately  to produce 
CBH, classic  delayed  hypersensitivity  (classic  DH), and/or antibodies  of  both 
passive  cutaneous  anaphylaxis  (PCA) and  hemolytic  types. 
Results  showed that  doses  of intravenous  antigen  sufficicnt  to induce  sub- 
sequent tolerance  for classic  DH  and hemolytic antibody actually  stimulatc 
CBH  reactivity  and PCA antibody  production. 
Other studies  of  dose-route  relationships  for CBH  production  demonstrated 
that  optimal  immunogenic dosage  requirements  for CBH  varied  widely  with 
route of antigen employed. OA in incomplete Freund's  adjuvant (IFA) in- 
jected  into  footpads  had low dosage requirements,  intravenous  OA had high 
dose requirements,  and intradermal soluble  OA  dosage requirements were 
intermediate. 640  CUTANEOUS BASOPHIL HYPERSENSITIVITY 
The observation that blatant imnmnogenic responses occur during the early 
period of tolerance induction amplifies the significant heterogeneity of the cellu- 
lar immune response and may be of importance in understanding tolerogenesis. 
Similar  immunogenic-tolerogenic  requirements  and  the  prime  role  played 
by  the  basophil  suggest  a  developmental  or  functional  relationship  between 
CBH and PCA antibody response. 
The author thanks  Dr. John C. Hoak for preparation  of the  electron  photomicrographs, 
and Miss Sue Newman for excellent technical assistance. 
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